The management team is a joke honestly. They have fumbled and bumbled there way through the last 2 years and want pay rises and performance shares.
It is laughable. The stock only goes one way and that is a direct result of their appalling management of what should be a blockbuster new drug and an exciting company to be invested in.
2022 PAR AGM, page-3
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
-0.005(1.79%) |
Mkt cap ! $96.19M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 28.5¢ | 27.0¢ | $55.31K | 200.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1072 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.5¢ | 3289 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |